Download Baker Ruskinn’s restart guide created by Baker’s Director of Scientific Applications to help correctly restart your workstation after an extended shutdown period.
Two potential vaccines will take part in an adaptive Phase I/II human clinical study. Two candidates including VBI-2901, a trivalent pan-coronavirus candidate expresses the SARS-CoV-2 and MERS CoV spike proteins, meanwhile, VBI-2902, a monovalent vaccine candidate expressing the SARS-CoV-2 spike protein. Find out more here.
Take a look at the publications database to view published papers that feature the InvivO2 workstation and other GROW products. Search by product or even your specific research type! Find out more.
It has been highlighted that Ebselen is able to block enzymes that the new COVID-19 needs to invade and replicate within healthy host cells. The drug is currently used to treat Bipolar Disorder and hearing loss and has anti-inflammatory properties. Find out more.
New and extensive research completed by the University of Bologna revealed that there are 6 strains of COVID-19. The first to appear was the L strain, followed by S, V and G. To date, the G strain is the most widely spread, with mutations including GR and GH. Read more.
The company, Mesoblast are currently working to show that cell therapy is effective in patients with acute respiratory distress syndrome (ARDS) caused by the SARS-CoV-2 virus. Find out more
This week’s topics from Dr. Ox include Hypoxia, Structures of Arabidopsis and restarting your laboratory after an extended shut down period. Make sure you follow Dr. Ox on Twitter for further updates.
Single domain antibodies otherwise known as nanobodies have recently been discovered as a potential treatment for COVID-19. The Australian Biotechnology company, The Beroni Group is currently preclinical testing. Find out more for yourself
Sign up to our monthly newsletter to stay up to date on everything that’s going on at Baker.